Results 81 to 90 of about 3,500 (185)

Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase

Clinical and Translational Science, Volume 18, Issue 12, December 2025.
ABSTRACT Janus kinase inhibitors (JAKIs) are immunomodulatory drugs used for autoimmune and inflammatory conditions. Their potential impact on pregnancy and fetal development remains a concern due to placental transfer and potential disruption of cytokine and growth factor signaling, with limited human data.
Nazanin Abolhassani, Roberta Noseda, Kim Dao, François R. Girardin, Francesca Bedussi, Alessandro Ceschi, Alice Panchaud, Ursula Winterfeld   +7 more
wiley   +1 more source

Targeted therapy of inflammatory bowel diseases: realities and prospects

Медицинский совет, 2018
This review article was designed to systematize the literature data concerning the role of targeted therapy in the treatment of patients with inflammatory bowel diseases.
I. V. Maev, D. N. Andreev
doaj   +1 more source

Filgotinib Demonstrates Efficacy in Rheumatoid Arthritis Independent of Smoking Status: Post Hoc Analysis of Phase 3 Trials and Claims-Based Analysis

Rheumatology and Therapy, 2023
Objectives To assess cigarette smoking’s effects on efficacy of the preferential Janus kinase (JAK) 1 inhibitor filgotinib and drug persistence in patients with rheumatoid arthritis (RA).
Jeffrey R. Curtis, Paul Emery, Bryan Downie, Yan Zhong, Jinfeng Liu, Ling Han, Rachael E. Hawtin, Gerd Rüdiger Burmester   +7 more
doaj   +1 more source

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study [PDF]

, 2017
Background Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor. Methods In this phase III, double-blind 24-week study, 684 biologic disease-modifying antirheumatic drug (DMARD)-naïve patients with rheumatoid arthritis and ...
Aletaha, Aletaha, Carol Gaich, Douglas Schlichting, Désirée van der Heijde, Edit Drescher, Eli Lilly and Company, Eli Lilly and Company, Eli Lilly and Company, Eli Lilly and Company, Eli Lilly and Company, Felson, Felson, Fries, Fries, Genovese, Genovese, Huizinga, Inmaculada de la Torre, Jiajun Liu, Keystone, Kremer, Maria Greenwald, Maxime Dougados, O'Shea, Papp, Paul Emery, Prevoo, Sarah Witt, Scott Beattie, Skoda, Smolen, Smolen, Smolen, Stephanie de Bono, Takeuchi, Tanaka, Terence Rooney, van der Heijde, van der Heijde, Westhovens, Yamane, Ying-Chou Chen, Zhang   +43 more
core   +2 more sources

Filgotinib in Active Noninfectious Uveitis [PDF]

JAMA Ophthalmology
ImportanceNoninfectious uveitis is a leading cause of visual impairment with an unmet need for additional treatment options.ObjectiveTo assess the efficacy and safety of filgotinib, a Janus kinase 1 (JAK1) preferential inhibitor, for the treatment of noninfectious uveitis.Design, Setting, and ParticipantsThe HUMBOLDT trial was a double-masked, placebo ...
Srivastava, Sunil K, Watkins, Timothy R, Nguyen, Quan Dong, Sharma, Sumit, Scales, David K, Dacey, Mark S, Shah, Rajiv E, Chu, David S, Grewal, Dilraj S, Faia, Lisa J, Suhler, Eric B, Genovese, Mark C, Guo, Ying, Barchuk, William T, Besuyen, Robin, Dick, Andrew D, Rosenbaum, James T   +16 more
openaire   +4 more sources

Exhaustion‐Resistant CD8 + T Cells in Ankylosing Spondylitis: A Proposed Three‐Axis Model

Immunology, Volume 176, Issue 4, Page 409-420, December 2025.
Exhaustion‐resistant CD8+ T cells may sustain ankylosing spondylitis. A three‐axis model—intermittent T‐cell receptor engagement, IL‐15/CD28 co‐stimulation and maintained metabolic fitness—explains how PD‐1^high CD8+ T cells retain effector function and accumulate from gut to entheses, promoting inflammation and aberrant bone remodelling.
Xuhong Zhang, Lu Jia, Xueni Lin, Lamei Zhou   +3 more
wiley   +1 more source

Breakfast skipping and steroid withdrawal in ulcerative colitis: A population‐based study in Japan

Physiological Reports, Volume 13, Issue 24, December 2025.
Abstract Ulcerative colitis (UC) is a chronic inflammatory bowel disease with increasing prevalence in Japan. While pharmacological therapies have advanced, the effect of dietary timing, particularly breakfast skipping, on disease course remains unclear.
Hiroshi Fukuda, Haru Miyagi, Kenta Yamamoto   +2 more
wiley   +1 more source

The extending scope of kinase inhibition in immune diseases [PDF]

, 2018
No abstract ...
McInnes, Iain B., Siebert, Stefan
core   +1 more source

Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement

Australasian Journal of Dermatology, Volume 66, Issue 7, Page e444-e460, November 2025.
ABSTRACT Over 5000 patients are newly diagnosed with Alopecia areata (AA) in Australia each year. AA severity varies from a single small patch to complete loss of scalp hair, body hair including eyelashes and eyebrows. Approximately 40% of affected individuals experience only a single patch and achieve spontaneous, complete and durable remission within
Daniella Kushnir‐Grinbaum, Laita Bokhari, John Frewen, Anthony Moussa, Daranporn Triwongwaranat, Ragini Ghiya, Flavia Rodrigues Dias, Shin Shen Yong, Bevin Bhoyrul, Zeyad Dabbagh, Ahmed Kazmi, Adam Daunton, Jane Li, Leona Yip, Vivian Lai, Katherine York, William Cranwell, Dmitri Wall, Samantha Eisman, Rodney Sinclair   +19 more
wiley   +1 more source

Current Management of Patients Taking Immunosuppressive Medication and Targeted Therapies: National Survey Within Oral Surgery and Oral and Maxillofacial Surgery

Oral Surgery, Volume 18, Issue 4, Page 472-479, November 2025.
ABSTRACT Introduction Systemic immunosuppressive medication and targeted therapies (IMTT) can increase the risk of surgical procedures to patients. The risks of continuing their systemic IMTT medication during the pre‐, peri‐ and post‐operative period must be weighed up against the risk of stopping their medication.
Kirsty Skye Dickson, Callum Wemyss, Alasdair Regan, Martin Paley, Arshad Siddiqui, Thomas Handley   +5 more
wiley   +1 more source